Ventas Inc., US92276F1003

Ventas stock (US92276F1003): Jefferies lifts price target to $100

Published on 05/13/2026 at 20:58 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Jefferies raised its price target on Ventas to $100 from $97 while maintaining a Buy rating, signaling confidence in the healthcare REIT's portfolio amid strong US market exposure.

Ventas Inc., US92276F1003, Illustration mit AI erstellt.
Ventas Inc., US92276F1003, Illustration mit AI erstellt.

Ventas stock drew attention after Jefferies adjusted its price target upward to $100 from $97 on May 13, 2026, while keeping its Buy rating intact, according to Marketscreener as of 05/13/2026. This move reflects optimism about the company's diversified healthcare real estate holdings, particularly its senior housing and outpatient facilities serving the aging US population.

As of: 13.05.2026

By the editorial team – specialized in equity coverage.

At a glance

  • Name: Ventas Inc.
  • Sector/industry: Specialized REITs
  • Headquarters/country: United States
  • Core markets: United States (89.3%), Canada (9.5%), United Kingdom (1.2%)
  • Key revenue drivers: Senior housing, outpatient care facilities
  • Home exchange/listing venue: NYSE (VTR)
  • Trading currency: USD

Official source

For first-hand information on Ventas, visit the company’s official website.

Go to the official website

Ventas: core business model

Ventas owns and manages a portfolio of healthcare-related properties, focusing on senior housing communities, outpatient facilities, and medical office buildings. At the end of 2025, the portfolio included 1,374 properties, with 752 dedicated to senior housing and 409 to outpatient care, per company disclosures as of year-end 2025. This structure positions Ventas as a key player in the real estate investment trust sector catering to aging demographics.

The REIT model allows Ventas to generate stable rental income from long-term leases with operators in the healthcare space, benefiting US investors through dividend payouts qualified under REIT regulations. Geographic revenue breakdown shows heavy US reliance at 89.3%, enhancing relevance for American portfolios tracking healthcare real estate trends.

Main revenue and product drivers for Ventas

Rent from senior living communities forms a core revenue pillar, driven by demand from the expanding elderly population in the US. Outpatient facilities contribute significantly, supporting ambulatory care needs amid shifts from inpatient services. These drivers align with broader healthcare spending growth projected in the US market.

Additional income stems from other assets like long-term acute care and inpatient rehabilitation facilities, comprising 213 properties as of end-2025. This diversification mitigates risks tied to any single subsector within healthcare real estate.

Industry trends and competitive position

The US senior living sector faces rising occupancy pressures but benefits from demographic tailwinds, with over-80 population expected to double by 2040. Ventas competes with peers like Welltower by emphasizing portfolio quality and operator partnerships, maintaining a competitive edge in high-demand regions.

Why Ventas matters for US investors

Ventas offers US investors targeted exposure to healthcare real estate, a defensive asset class amid economic cycles. With 89.3% of revenues from the US, the company directly ties to domestic healthcare spending, which represents a significant GDP portion and influences REIT performance on NYSE.

Conclusion

Jefferies' price target increase to $100 underscores analyst faith in Ventas' strategic positioning within healthcare REITs. The company's extensive US-focused portfolio supports steady income streams for investors monitoring demographic shifts. Market dynamics, including occupancy trends and operator health, will shape near-term performance.

Read more

Additional news and developments on the stock can be explored via the linked overview pages.

More news on this stockInvestor relations

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.

Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.

en | US92276F1003 | VENTAS INC. | boerse | 69327687 | bgmi